Skip Navigation

European Heart Journal 1990 11(Supplement H):26-31; doi:10.1093/eurheartj/11.suppl_H.26
Copyright © 1990 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mänttäri, M.
Right arrow Articles by Frick, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mänttäri, M.
Right arrow Articles by Frick, M. H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 The European Society of Cardiology

Lipoproteins and coronary heart disease in the Helsinki Heart Study

M. Mänttäri, J. K. Huttunen, P. Koskinen, V. Manninen, L. Tenkanen, O. P. Heinonen and M. H. Frick

First Department of Medicine and the Department of Public Health, University of Helsinki, and the National Public Health institute of Finland Helsinki, Finland

Address for correspondence: Juan K. Huttunen, MD, National Public Health Institute, Mannerhtheimintie 166, SF-00300 Helsinki, Finland

The changes in serum lipids in men treated with gemfibrozil in the Helsinki Heart Study, a controlled primary prevention trial of coronary heart disease, varied according to baseline lipid levels, type of dyslipidaemia, and treatment compliance. in subjects with the best treatment compliance, gemfibrozil induced mean decreases of 14% in total cholesterol, 15% in low density lipoprotein (LDL)-cholesterol, and 45% in triglycerides, and a mean increase of 14% in high density lipoprotein (HDL)-cholesterol, compared with placebo. These changes were significantly greater than those observed in the entire cohort. There was a strong association between baseline levels and the response to treatment (expressed as the difference in mmoll–1 between the gemfibrozil and placebo-treated groups) for LDL-cholesterol and triglycerides. In contrast, the corresponding change in HDL-cholesterol was not dependent on the baseline level. Ultracentr analysis in a subsample of the cohort revealed that gemfibrozil raised the level of HDL3 -cholesterol but had little effect on HDL2-cholesterol. The gemfibrozil-associated reduction in the incidence of definite coronary events varied according to lipid values at baseline and their changes during treatment. The greatest reductions were seen in subjects with low initial HDL-cholesterol and high initial triglycerides. in the gemfibrozil group, the increase in HDL-cholesterol and decrease in LDL-cholesterol were associated with significantly lower risk of coronary events.

Key Words: Cornary heart disease • lipproteins • gemfibrozil • Helsinki Heart Study


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Physiol.Home page
W. H. Cooke, C. A. Rickards, K. L. Ryan, T. A. Kuusela, and V. A. Convertino
Muscle sympathetic nerve activity during intense lower body negative pressure to presyncope in humans
J. Physiol., October 15, 2009; 587(20): 4987 - 4999.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
F. Compton and J.-H. Schafer
Noninvasive Cardiac Output Determination: Broadening the Applicability of Hemodynamic Monitoring
Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2009; 13(1): 44 - 55.
[Abstract] [PDF]


Home page
EuropaceHome page
B.M.T. Deegan, M. O'Connor, T. Donnelly, S. Carew, A. Costelloe, T. Sheehy, G. OLaighin, and D. Lyons
Orthostatic hypotension: a new classification system
Europace, October 1, 2007; 9(10): 937 - 941.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. A. Rickards, K. L. Ryan, W. H. Cooke, K. G. Lurie, and V. A. Convertino
Inspiratory resistance delays the reporting of symptoms with central hypovolemia: association with cerebral blood flow
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R243 - R250.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
J. P. Fisher, S. Ogoh, E. A. Dawson, P. J. Fadel, N. H. Secher, P. B. Raven, and M. J. White
Cardiac and vasomotor components of the carotid baroreflex control of arterial blood pressure during isometric exercise in humans
J. Physiol., May 1, 2006; 572(3): 869 - 880.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
R. Aardenburg, M. E. Spaanderman, H. W. van Eijndhoven, P. W. de Leeuw, and L. L. Peeters
Formerly Preeclamptic Women With a Subnormal Plasma Volume Are Unable to Maintain a Rise in Stroke Volume During Moderate Exercise
Reproductive Sciences, December 1, 2005; 12(8): 599 - 603.
[Abstract] [PDF]


Home page
Reproductive SciencesHome page
R. Aardenburg, M. E. Spaanderman, D. A. Courtar, H. W. van Eijndhoven, P. W. de Leeuw, and L. L. Peeters
A Subnormal Plasma Volume in Formerly Preeclamptic Women is Associated with a Low Venous Capacitance
Reproductive Sciences, February 1, 2005; 12(2): 107 - 111.
[Abstract] [PDF]


Home page
J. Physiol.Home page
L Kornet, J R C Jansen, F C A M te Nijenhuis, G J Langewouters, and A Versprille
The compliance of the porcine pulmonary artery depends on pressure and heart rate
J. Physiol., November 1, 1998; 512(3): 917 - 926.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. P.M. Imholz, W. Wieling, G. A. van Montfrans, and K. H. Wesseling
Fifteen years experience with finger arterial pressure monitoring:: assessment of the technology
Cardiovasc Res, June 1, 1998; 38(3): 605 - 616.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
S. M. Grundy and G. L. Vega
Two Different Views of the Relationship of Hypertriglyceridemia to Coronary Heart Disease: Implications for Treatment
Arch Intern Med, January 1, 1992; 152(1): 28 - 34.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.